Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of MGD020 as a Single Agent or in Combination With MGD014 in Persons With HIV-1 on Antiretroviral Therapy

NCT05261191 is registered in ClinicalTrials.gov with MacroGenics as lead sponsor.

NCT NCT05261191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05261191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of MGD020 as a Single Agent or in Combination With MGD014 in Persons With HIV-1 on Antiretroviral Therapy
Lead sponsor
MacroGenics
Phase
Phase 1
Overall status
Completed
Start date
September 26, 2022
Completion date
May 29, 2024
Enrollment
17 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus i infection, human immunodeficiency virus type 1, immunodeficiency virus type 1, human